INTRODUCTION
============

As first described by Shulman in 1974,[@R112] eosinophilic fasciitis (EF) is a rare connective tissue disease characterized by symmetrical swelling and progressive thickening and stiffness of the subcutaneous tissue, leading to a dimpled, "peau d'orange" presentation of the skin. Myalgia, inflammatory polyarthralgia, pedal and lower extremity edema and morphea are also commonly reported.[@R75] The hands may be affected by skin sclerosis, but facial involvement is rarely observed. Visceral involvement, Raynaud phenomenon, telangiectasia, calcinosis cutis, and nail-fold capillaroscopy abnormalities are very uncommon in EF,[@R53] usually enabling its distinction from systemic sclerosis. In up to half of the cases, the onset of symptoms seems to follow a vigorous level of exercise to which the patient was unaccustomed. Peripheral eosinophilia and hypergammaglobulinemia are often present.[@R75] A definitive diagnosis relies on histopathologic observation of modifications of the fascia and lower subcutis, including edema and infiltration by plasma cells, lymphocytes, histiocytes, and eosinophils; later, these changes manifest as thickening and collagenization of the fascia. These alterations can extend into the dermis and underlying muscle.[@R8] The dermatologic prognosis after corticosteroid therapy is usually good, with complete remission in most patients, yet persistent disability resulting from residual fibrosis occurs in 29%--42% of cases.[@R37],[@R76]

EF is sometimes associated with hematologic diseases, particularly with aplastic anemia (AA) (n = 19),[@R2],[@R13],[@R15],[@R22],[@R24],[@R30],[@R33],[@R38],[@R57],[@R58],[@R73],[@R77],[@R89],[@R95],[@R111],[@R117],[@R128] but also with T-cell lymphoma (n = 5),[@R27],[@R36],[@R65],[@R72],[@R83] cutaneous T-cell lymphoma (n = 1),[@R25] Hodgkin disease (n = 3),[@R84],[@R90],[@R98] myeloproliferative syndromes (n = 3),[@R61],[@R75],[@R85] myelomonocytic leukemia (n = 2),[@R75],[@R85] chronic lymphocytic leukemia (n = 2),[@R12],[@R75] multiple myeloma (n = 1),[@R68] and myeloblastic leukemia (n = 1),[@R90] and, less commonly, with solid tumors such as breast cancer (n = 5),[@R12],[@R90],[@R109],[@R127] choroidal melanoma (n = 1),[@R125] colorectal cancer (n = 1),[@R94] and prostate cancer (n = 1).[@R90] Diffuse EF has also been reported in association with autoimmune disorders, such as Hashimoto thyroiditis (n = 6),[@R2],[@R5],[@R13],[@R59],[@R114] systemic lupus erythematosus (n = 4),[@R6],[@R43],[@R45],[@R74] Crohn disease (n = 1),[@R82] Graves disease (n = 1),[@R114] glomerulonephritis (n = 1),[@R63] rheumatoid arthritis (n = 1),[@R81] type 1 diabetes (n = 1),[@R46] and autoimmune cytopenias, including autoimmune hemolytic anemia (n = 2),[@R5],[@R44] immune thrombocytopenic purpura (n = 2),[@R5],[@R111] amegakaryocytic thrombocytopenia (n = 2),[@R26],[@R48] and pure red-cell aplasia (n = 1).[@R81]

It is still uncertain whether AA associated with EF is an autoimmune disease and/or the initial manifestation of an evolving clonal myeloid disorder. Among the 19 reported patients with EF and associated AA,[@R2],[@R13],[@R15],[@R22],[@R24],[@R30],[@R33],[@R38],[@R57],[@R58],[@R73],[@R77],[@R89],[@R95],[@R111],[@R117],[@R128] 8 died of complications from AA. Although most of these deaths occurred in patients receiving corticosteroids and/or antithymocyte globulin (ATG)-based regimens (without cyclosporine A \[CsA\]) in the 1980s, the current conventional immunosuppressive therapy of ATG and CsA was ineffective in 3 of 6 (50%) cases. We report 4 patients with severe aplastic anemia (SAA) and EF and provide a comprehensive review of the literature, focusing on clinical presentation, therapeutic challenges, and the outcomes of AA associated with EF.

PATIENTS AND METHODS
====================

Between 1996 and 2012, 4 patients with EF and associated SAA were analyzed retrospectively at 4 French university hospitals. All of the patients had clinical and histopathologic features of EF, together with pancytopenia and, upon bone marrow examination, marked hypocellularity, and they fulfilled the established criteria for SAA diagnosis.[@R19] Two of these patients[@R15],[@R33] have been previously reported, and we provide additional information on their clinical features and long-term follow-up.

We searched the National Library of Medicine's MEDLINE database (Bethesda, MD) for relevant literature using the keywords "fasciitis" and "Shulman syndrome" together with "aplastic anemia" and "pancytopenia." The bibliographies of all the selected articles were reviewed for additional case reports. We selected 19 patients from 15 different articles published between 1978 and 2009 in the English, French, German, and Portuguese literature.[@R2],[@R13],[@R22],[@R24],[@R30],[@R38],[@R57],[@R58],[@R73],[@R77],[@R89],[@R95],[@R111],[@R117],[@R128] Patients were selected if they displayed clinical features of EF and pancytopenia and if AA was confirmed by bone marrow examination. The diagnosis of EF was confirmed by a deep skin biopsy, including the fascia, in all but 2 cases. In 1 case, a deep skin biopsy was not performed because of the risk of bleeding due to profound refractory thrombocytopenia;[@R24] in another case,[@R117] the deep skin biopsy was not conclusive, but it was performed after corticosteroid and ATG administration.

The clinical characteristics of the patients in the present and in previous reports were recorded and compared to those of 86 patients with EF and without AA from the benchmark Lakhanpal clinical series (n = 52)[@R75] and from a more recent retrospective clinical study (n = 34).[@R76] Three major caveats should be noted regarding the interpretation: there was a lack of in-depth clinical descriptions in some cases, there was possible over-reporting of unusual clinical features in the case reports compared to the clinical series, and there was a lack of long-term follow-up data in many of the case reports. Therefore, a statistical analysis was not performed.

When available, skin and hematologic outcomes were assessed using the following criteria: remission (defined as the absence of residual clinical signs of EF or as transfusion independence), long-term remission (longer than 2 yr after the start of the treatment), improvement (without complete remission), no improvement, and AA-related death.

CASE REPORTS
============

Patient 1
---------

A 65-year-old retired beautician experienced petechiae, nosebleeds, and hemorrhagic bullae of the oral mucosa. She reported a 6-month history of asthenia, weight loss, myalgia, and progressive stiffness of the skin, which the patient reported had started after a swim in a river. She had been exposed to pentachlorophenol and lindane for 20 years, which are 2 pesticides used to treat lumber beams in her house. A physical examination revealed firm induration of the subcutaneous tissue, including the digits but sparing the face. There was a peau d'orange appearance of the back and venous furrowing (groove sign) ofthe anterior part of the forearms. There was no evidence of Raynaud phenomenon, dyschromia, telangiectasia, calcinosis cutis, or gastroesophageal reflux. A complete blood count disclosed pancytopenia (Hb: 8.8 g/dL; reticulocytes: 27 g/L; leukocytes: 2 g/L: neutrophils: 0.55 g/L; and platelets: 11 g/L). A bone marrow biopsy showed global hypoplasia with T lymphocyte and eosinophil infiltration. No paroxysmal nocturnal hemoglobinuria (PNH) clone was detected by flow cytometry. The antinuclear antibody titer was 1:80, and no antibodies to extractable nuclear antigens were detected, including anti-Scl70 or anticentromere antibodies. The direct Coombs test was positive with an anti-IgG antibody reagent. When the patient was admitted to the hospital, she required daily platelet transfusions, partly due to anti-HLA class I allo-sensitization. She received 3 mg/kg ATG and 2 mg/kg prednisone for 5 days and was discharged on 340 mg of oral CsA daily, weekly subcutaneous romiplostim injections, monthly intravenous immunoglobulin infusions, and platelet transfusional support 3 times per week. Six months later, her skin abnormalities had completely resolved. After transient hematologic improvement, a relapse occurred, and she required weekly platelet transfusions for 9 months after ATG treatment. Blood marrow aspiration showed persistent severe hypoplasia with 20% cellularity.

Patient 2
---------

After a week of snowshoeing, a 57-year-old farm worker developed asthenia, myalgia, and rapidly progressive thickening of the skin on the trunk and on all 4 limbs. A physical examination revealed diffuse scleroderma, except on his face, with peau d'orange presentation of the abdomen (Figure [1](#F1){ref-type="fig"}) and thighs and venous furrowing of the forearms. The eosinophil count was 2.6 g/L. Three months after the onset of these symptoms, a full-thickness skin and muscle biopsy from the arm revealed perivascular lymphoplasmacytic infiltration of the hypodermis, fascia, and perimysium, indicative of EF (Figure [2](#F2){ref-type="fig"}). The patient was discharged on prednisone (1 mg/kg daily). Two months later, he was readmitted with diffuse petechiae and ecchymoses of the lower limbs. His platelet count was 7 g/L, hemoglobin 9.9 g/dL, reticulocytes 55 g/L, leukocytes 1.2 g/L, and neutrophils 0.4 g/L. Bone marrow aspiration disclosed severe hypocellularity (\<20%) with a complete absence of megakaryocytes (Figure [3](#F3){ref-type="fig"}). He received ATG for 5 days, and a daily oral dose of 360 mg CsA was started. The CsA dose was tapered to 200 mg daily 6 months later after the onset of an axonal sensory polyneuropathy of the lower limbs, presumably of toxic origin. One year later, his skin condition did not improve, and he still required weekly transfusional support related to persistent anemia (Hb: 10.4 g/dL) and thrombocytopenia (platelets: 9 g/L). A second bone marrow aspiration disclosed moderate hypocellularity and an absence of megakaryocytes. He was given rituximab at a dose of 375 mg/m^2^ per week for 4 weeks, followed by cytopenia regression (Hb: 12 g/dL and platelets: 97 g/L) and transfusion withdrawal within 3 months. A relapse occurred, however, 6 months after the first course, and he received 4 more infusions of rituximab using the same protocol. Once again, the cytopenias improved, and transfusional support could be withdrawn. After the second course, the skin abnormalities resolved completely. CsA was tapered to 80 mg daily, and no relapse occurred during the 6 months of additional follow-up.

![Patient 2. Dimpled, peau d'orange aspect of the abdomen. \[This figure can be viewed in color online at <http://www.md-journal.com>\].](md-92-069-g001){#F1}

![Patient 2. Full-thickness skin and muscle biopsy from the arm. Lymphoplasmocytic infiltrate of the fascia and lower subcutis with few eosinophils, consistent with EF at early stage (hemalun-eosin stain, ×250 magnification). \[This figure can be viewed in color online at <http://www.md-journal.com>\].](md-92-069-g002){#F2}

![Patient 2. Bone marrow biopsy. Fatty, severely hypoplastic marrow with complete absence of megacaryocytes and a discrete lymphocytic inflammatory infiltrate (hemalun-eosin stain, ×100 magnification). \[This figure can be viewed in color online at <http://www.md-journal.com>\].](md-92-069-g003){#F3}

Patient 3
---------

A 35-year-old bricklayer experienced a rapid onset (a few days) of painful swelling of the limbs, arthralgia, and myalgia. He reported no previous physical stress. A clinical examination revealed thickening of the skin and subcutaneous tissue involving the trunk and all 4 limbs, including the digits. Laboratory studies revealed eosinophilia (1.15 g/L), an elevated erythrocyte sedimentation rate (23 mm/h), and polyclonal hypergammaglobulinemia (20 g/L). The antinuclear antibody titer was \<1:80, with no antibodies to extractable nuclear antigens, including anti-Scl70 and anticentromere antibodies. A leg fascial biopsy showed a mononuclear infiltration of lymphoplasmocytes and eosinophils involving the perimysial tissue and the fascia, confirming the diagnosis of diffuse EF. The epidermis was normal, whereas thickened collagen bundles were observed in the dermis as were straightening with parallel orientation of the elastic fibers. Daily treatment with 1 mg/kg prednisone was started. Eight months later, he experienced massive hematemesis and was admitted to the intensive care unit. An esophago-gastroduodenoscopy revealed a normal esophagus, hematin-covered gastric lesions and a gastric ulcer with an adherent clot. His full blood count showed aplastic anemia (hemoglobin 8.3 g/dL, reticulocytes 36 g/L), platelets 3 g/L, and leukocytes 1.8 g/L. A bone marrow biopsy confirmed the diagnosis of SAA. There was no PNH clone detected. After 9 months of prednisone therapy, his skin condition did not improve, and the patient required blood and platelet transfusions every 2 weeks. A clinical examination showed diffuse sclerosis of the skin and subcutaneous tissue, including sclerodactyly, affecting 90% of the total body surface area (Figure [4](#F4){ref-type="fig"}A). Venous furrowing (groove sign) was visible on the forearms, and the skin seemed dimpled with a peau d'orange appearance. The nipples, palms, and plantar surfaces were not affected. The edema and arthralgia resolved. A careful examination of the neck revealed patchy, ivory, atrophic lesions with a pigmented peripheral halo, indicative of guttate morphea. Raynaud phenomenon was present. Microhemorrhages, edema, giant capillaries, a decreased number of capillary loops and avascular areas were found on nail-fold capillaroscopy consistent with an organic microangiopathy. Neither gastroesophageal reflux nor renal failure was observed. Echocardiography revealed increased systolic pulmonary arterial pressure (41 mm Hg) with normal left ventricular function. The lung diffusion capacity for carbon monoxide was reduced (47% of the predictive value). High-resolution computed tomography of the chest was normal. The skin abnormalities gradually subsided (Figure [4](#F4){ref-type="fig"}B), but immunosuppressive therapy (2 courses of ATG plus CsA 5 mg/kg) failed to improve the aplasia after 24 months of follow-up. Unfortunately, no compatible donor was found for allogeneic hematopoietic stem cell transplantation (HSCT). The patient had severe *Pseudomonas aeruginosa* mastoiditis that required surgery and antibiotic treatment with partial sterilization; he then developed invasive pulmonary aspergillosis. He was still alive at the last follow-up.

![Patient 3. Redness, warmth, and woody induration of the skin of the left forearm (top). After 12 months of immunosuppressive therapy (bottom). Marked softening of the skin; veins have become visible. \[This figure can be viewed in color online at <http://www.md-journal.com>\].](md-92-069-g004){#F4}

Patient 4
---------

A 60-year-old man developed asthenia, weight loss, myalgia, pruritus, and progressive skin stiffness of his abdomen, limbs, and the superior part of the back. He was an insurer and reported no long-term exposure to toxins and no previous physical stress. His past history included a deep vein thrombosis of the left leg 3 months earlier and ulcerative colitis in remission. He was diagnosed with ulcerative colitis 6 years ago and was treated with corticosteroids; the dose had been decreased from 20 to 1 mg daily during the previous year. A physical examination showed thickening of the subcutaneous thigh tissue and deep morphea of the legs and forearms. Hypo- and hyperpigmentation of the thighs were also observed. His face and digits were not affected, and there was no Raynaud phenomenon. The nail-fold capillaroscopy was normal. Fluctuating eosinophilia (maximum: 2.5 g/L) and an elevated erythrocyte sedimentation rate (50 mm/h) had been found during the onset of symptoms. Antinuclear antibodies, antibodies to extractable nuclear antigens, including anti-Scl70 and anticentromere antibodies, were absent. A deep skin biopsy showed edema and thickened collagen bundles in the hypodermis as well as a dense lymphoplasmacytic infiltrate, mainly around the capillaries in the hypodermis, fascia, and muscle walls. The same alterations were also noticed in the deep dermis, whereas the epidermis appeared normal. The corticosteroid dose was increased to 80 mg daily with no efficacy after 3 months. He was readmitted for fever 8 months after the onset of these symptoms, and a complete blood count disclosed aplastic anemia (Hb: 7.6 g/dL), leukopenia (leukocytes: 2.9 g/L), neutropenia (neutrophils: 0.7 g/L), and severe thrombocytopenia (platelets: 30 g/L). Antiplatelet glycoprotein IgG antibodies, detected using the monoclonal antibody-specific immobilization of platelet antigens assay, were present. Bone marrow aspiration revealed severe hypocellularity (\<20%) and an absence of megakaryocytes. Fever resolution occurred after the patient was placed on empirical antibiotic therapy. He received ATG (300 mg/d) and CsA (4 mg/kg per d) for 5 days. One year later, his skin and hematologic conditions had normalized. The CsA dosage was gradually decreased and was stopped 8 years later. Four years after CsA withdrawal, he developed autoimmune hemolytic anemia (Hb: 7.6 g/dL; reticulocytes: 101 g/L; LDH: 552 IU/L, Direct Coombs test: positive using anti-IgG antibody reagent), which responded well to oral corticosteroids.

DISCUSSION AND LITERATURE REVIEW
================================

Age, Sex, and Environmental Factors
-----------------------------------

Among the 23 patients with EF and concomitant AA from previous and present reports, most were aged more than 60 years (Table [1](#T1){ref-type="table"}). The mean age was 56 years (range, 18--71 yr). Only 3 patients were under 40 years of age when they were diagnosed with EF. Of the 23 patients, 16 (70%) were men. These results contrast with the clinical characteristics of EF patients without associated AA,[@R75],[@R76] who tended to be younger (mean age, 47 yr[@R75] or 53 yr[@R76]) and were more often women (66%[@R75] or 59%[@R76]). As in the Lakhanpal case series, patients with EF and AA were most often white.

###### 

Clinical Features of Patients With EF and Associated AA and Patients With EF Without Associated AA

![](md-92-069-g005)

The professions of 11 patients were specified. Eight were manual workers: 3 were farm workers (Patient 2 and patients reported previously[@R58],[@R77]), 1 a foundry worker,[@R58] 1 a dry cleaner,[@R58] 1 a mechanic,[@R38] 1 a brick mason (Patient 3), and 1 a beautician (Patient 1). Patient 1 reported exposure to lindane and pentachlorophenol for 20 years, which are 2 organochlorine pesticides used for wood preservation; these agents have been implicated in other reported cases of isolated AA.[@R16],[@R99] We are unaware of other reported cases of EF and AA following exposure to pesticides, but 1 case of AA and diffuse scleroderma following exposure to paradichlorobenzene and naphthalene in an employee of a clothing resale shop has been reported.[@R50] These observations led us to speculate on the potential role of toxic exposure in the onset of the disease, although it must be remembered that no definitive conclusion can be drawn based on relatively few cases.

Benzene exposure[@R80] and exposure to agricultural pesticides[@R60] have been clearly shown to be linked to AA in case-control studies. The role of environmental factors has also been suspected in the context of EF, although no case-control study is available. In case reports, EF has been linked to infection with *Borrelia species*,[@R2],[@R9],[@R47],[@R51],[@R87],[@R107],[@R116] brucellosis,[@R90] chronic hepatitis C,[@R90] tertiary syphilis,[@R90] chemical exposure,[@R11] trichloroethylene,[@R52] insect bites,[@R79],[@R90] irradiation,[@R109] and various pharmaceuticals, including simvastatin,[@R28],[@R108] phenytoin,[@R18] atorvastatin,[@R31] fosinopril,[@R10] alpha-methyldopa,[@R90] subcutaneous heparin use,[@R20] and antituberculosis therapy.[@R104] Geographical clustering of scleroderma-like syndromes, including EF, was reported in a rural area in Italy.[@R124] More importantly, eosinophilia-myalgia syndrome, which includes myalgia, scleroderma, constant peripheral eosinophilia, fasciitis in 25%--55% of cases, and sometimes severe peripheral neuropathies, is linked to L-tryptophan ingestion.[@R54] Similarly, adulterated cooking oils have induced toxic-oil syndrome, which presents with myalgia, diffuse scleroderma, and peripheral eosinophilia, yet to our knowledge no associated fasciitis has ever been reported.[@R70]

Clinical Features at EF Diagnosis
---------------------------------

Progressive skin stiffness was present in all 23 patients (see Table [1](#T1){ref-type="table"}), with peau d'orange presentation in 9 cases. The digits were involved in 7 cases. Seven patients also reported weight loss, although this symptom was not reported in patients with EF from the Lakhanpal case series.[@R75] It is likely, however, that it was simply not recorded in that particular case series; it was reported in 9 of 34 patients with EF (26%) in the retrospective clinical study from Lebeaux et al.[@R76]

Other clinical features of EF, such as pitting edema of the lower legs, inflammatory arthritis, a groove sign, carpal tunnel syndrome, and morphea plaques, were rarely reported in patients with EF and AA, but this finding could be related to the scarcity of in-depth clinical descriptions.

Uncommon clinical features of EF were found in 10 patients. One patient had lymphadenopathy.[@R58] A lymph-node biopsy showed lymphoid and reticular hyperplasia. Lymphadenopathy is rarely associated with EF; in a case series of 10 patients with EF and peripheral lymphadenopathy,[@R91] lymph-node biopsies revealed lymphoma in 6 cases.

Two patients exhibited seritis, including ascites and pleural effusion[@R89] or pericarditis.[@R22] Rare cases of EF with pleural[@R71] or pericardial[@R92] involvement, or both,[@R97] have been described previously. Two patients had peripheral neuropathy (our Patient 2 and a patientfrom the literature[@R30]). However, in our patient, the role of cyclosporine toxicity could not be excluded. Three cases of EF with associated peripheral neuropathy have been reported.[@R86],[@R101],[@R106]

One patient had acute, unilateral nongranulomatous iritis,[@R58] and 1 patient had bilateral chemosis.[@R89]

One patient had dyschromia, microstomia, and dysphagia.[@R38] Similarly, Patient 3 had dyschromia, Raynaud phenomenon, and nail-fold capillaroscopy abnormalities. Finally, 1 patient exhibited calcinosis cutis.[@R24] These features are unusual in EF and can complicate the differentiation of this disease from systemic sclerosis. Moreover, apart from EF, 9 cases of diffuse scleroderma have been reported in association with AA[@R7],[@R14],[@R21],[@R29],[@R39],[@R41],[@R66],[@R118],[@R122] or amegakaryocytic thrombocytopenia.[@R67] None of these patients had been diagnosed with EF. One patient had Raynaud phenomenon.[@R39] One had lung carcinoma and esophageal hypomotility.[@R41] Another patient[@R29] had Crohn disease, Raynaud phenomenon, esophageal dysmotility, and interstitial lung disease. These findings further blur the boundaries between EF, diffuse morphea, and systemic sclerosis, as these 3 diseases seem to be associated with AA; however, AA is more frequently associated with EF than the 2 other conditions.

Associated Immune Diseases
--------------------------

Four patients (17%) had prior immune disease diagnoses. Two patients had Hashimoto thyroiditis,[@R2],[@R13] and 2 others (Patient 4 and a patient reported previously[@R30]) had ulcerative colitis. Hashimoto thyroiditis[@R5],[@R13],[@R59],[@R114] and Crohn disease[@R82] have been previously reported as associated with EF but not AA in some case reports. AA is rarely associated with other immune diseases; in a retrospective survey of 1251 patients with AA, only 50 (4%) had prior autoimmune disease diagnoses.[@R23] AA has been reported, however, in association with autoimmune enteropathy.[@R100]

Hematologic Involvement
-----------------------

In most cases, the interval between the diagnosis of EF and the onset of AA was less than 6 months (mean delay, 7.2 mo; median, 4 mo; range, 0--60 mo) (Table [2](#T2){ref-type="table"}). In 8 cases, EF and AA were diagnosed simultaneously. AA was revealed by cutaneomucosal hemorrhagic syndrome in 14 cases. Among these cases, 2 patients experienced massive gastrointestinal bleeding (hematemesis in Patient 3, hematemesis and melena in a patient from the literature[@R24]). In 3 cases, the patients presented with sepsis caused by undocumented pneumonia (Patient 4 and from the literature[@R73]) and *Streptococcus fecalis* periorbital cellulitis.[@R77] In 5 patients, AA was discovered fortuitously by a complete blood count. Marrow hypocellularity was described as "profound,"[@R30] "marked,"[@R58] or "severe"[@R58],[@R73],[@R89] in 7 cases. Marrow cellularity was \<20% in 6 additional cases (4 patients in the current study and 2 previously described[@R22],[@R24]) and was 30% in another case;[@R128] cellularity was not specified in the remaining cases. Two patients also had positive direct Coombs test results (Patient 1 and a patient previously described[@R58]). Patient 4 tested positive for antiplatelet glycoprotein IgG antibodies, detected using the monoclonal antibody-specific immobilization of platelet antigens assay, and this patient developed autoimmune hemolytic anemia several years later. Yet another patient[@R128] had platelet IgG antibodies as determined by complement lysis inhibition.

###### 

Clinical Characteristics, Management, and Outcome of 23 Patients With EF-Associated AA
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Normal marrow cultures from healthy donors in the presence of diseased patient's serum were performed in 4 cases.[@R57],[@R73],[@R128] There was 90% inhibition of CFU-GM growth in the first case,[@R73] no inhibition of myeloid progenitor cell growth in the second,[@R73] inhibition of BFU-E and CFU-E growth in the third,[@R128] and 92%, 100%, and 83% inhibition of CFU-M, CFU-E, and BFU-E growth, respectively, in the fourth case.[@R57] Inhibition of myeloid progenitor cell growth was found to be restricted to the IgG fraction of the patient's serum in the latter experimental condition.[@R57] Co-cultures of the patient's and healthy donors marrow cells were performed in 5 patients,[@R73],[@R128] and stem cell colony growth suppression was absent in all but 1 case, in which growth of CFU-E was 40%--75% of the predicted value.[@R128] Finally, AA can coexist or evolve into clonal disorders such as PNH, myelodysplasia, or acute myeloblastic leukemia.[@R130] Detection of a PNH clone was sought but not found in 3 of our patients (Patients 1, 3, and 4). No clonal myeloid disorders were described in 23 patients with EF and AA. However, apart from this literature review, there have been 3 reports of EF patients who experienced pancytopenia in whom an excess of blast cells,[@R48] an evolving myeloproliferative process,[@R34] or myelomonocytic leukemia[@R34] were found upon bone marrow examination.

Pathophysiology
---------------

In general, AA is considered an autoimmune disease involving interferon-γ-secreting Th1[@R113] and IL-17-producing Th17[@R32] CD4 T cells as well as oligoclonal cytotoxic CD8 T cells,[@R96] leading to the destruction of autologous hematopoietic stem and progenitor cells.[@R130] Moreover, regulatory T cells (Tregs), which control and suppress autoreactive T cells, are decreased at disease presentation in almost all AA patients, suggesting their involvement in AA pathophysiology.[@R115] Specific autoantibodies to kinectin,[@R56] diazepam-binding inhibitor-related protein 1,[@R40] postmeiotic segregation-increased protein 1,[@R55] and moesin[@R120] have been found in the serum of patients with AA. Moesin is a cytoskeleton-membrane linker protein that is expressed on the surface of T cells, NK cells, and monocytes. Antimoesin antibodies have been shown to stimulate interferon-γ secretion from peripheral mononuclear cells retrieved from AA patients in vitro;[@R119] therefore, these antibodies may contribute to AA pathophysiology. Abnormalities in telomere repair have also been identified in acquired AA patients.[@R17] Telomeres are nucleotide repeats at the ends of the chromosomes that function as protective caps to prevent erosion of genomic DNA during cell division. Each time a cell divides, the telomeres shorten. When they become too short, the cell can no longer divide and becomes inactive. Critically short telomeres produce apoptosis, cell senescence, and chromosomal instability. Mutations in telomerase complex genes resulting in extremely short telomeres have been described in some patients with AA.[@R129] In acquired AA, independent of known genetic alterations, the presence of short telomeres in leukocytes at the time of presentation affects the clinical course: patients with short telomeres respond to immunosuppressive interventions, but their relapse rate is almost double that of cases with normal telomere length. Additionally, virtually all clonal evolution occurs in patients in the lowest quartile of telomere length.[@R103]

EF is also believed to be an immune-mediated disease. This conclusion is supported by the following evidence: 1) histologic features (cytotoxic CD8 T-lymphocytic, monocytic, and eosinophilic infiltrates[@R123] and IgG and C3 deposits[@R8]); 2) the disease's association with other autoimmune diseases (autoimmune cytopenias, thyroiditis, or systemic lupus erythematosus); 3) the disease's association with biologic abnormalities (polyclonal hypergammaglobulinemia[@R75] and circulating immune complexes[@R105]); and 4) reported cases of fasciitis in the context of alloimmunity during chronic graft-versus-host disease after allogeneic stem cell transplantation.[@R62] To date, few specific studies have been performed on the immune regulation of EF. However, this disease belongs to the group of localized scleroderma, also referred to as morphea or skin scleroderma,[@R93] as illustrated by the association of plaque morphea with EF.[@R75],[@R76] Localized scleroderma is characterized by increased collagen deposition (fibrosis), which differs from systemic sclerosis in which collagen deposition and vasculopathy are predominant features. Nonetheless, systemic sclerosis shares clinical and pathophysiologic features with EF, such as increased serum levels of TGF-β, a potent profibrotic cytokine,[@R35],[@R42] and elevated levels of inhibitors of metalloproteinases in the affected tissues.[@R64],[@R69] Increased production of Th1 (that is, IL-2 and interferon-γ) and Th2 (that is, IL-5 and IL-10) cytokines have been found in EF patients after stimulation.[@R126] Fewer circulating Tregs have been described in patients with systemic sclerosis and localized scleroderma in comparison with healthy individuals.[@R3] Defects in telomerase biology have been described in systemic sclerosis with contradictory results.[@R4],[@R78] Dysregulation of B-cell homeostasis has been described in chronic graft-versus-host disease,[@R110] and fasciitis similar in symptomology to EF is frequent in chronic graft-versus-host disease.[@R62]

To summarize, pathophysiologic links between EF and AA may involve the following: 1) increased CD8 and Th1/Th17 T-cell responses, 2) decreased Tregs, 3) abnormal telomere repair homeostasis, and 4) dysregulated B-cell responses with autoantibody production, which may explain the potential benefit of rituximab in 1 of our patients.

Treatment and Outcome
---------------------

At least 8 patients died of complications from AA[@R22],[@R58],[@R73],[@R77],[@R89] (Table [3](#T3){ref-type="table"}). Death occurred after a mean interval of 4 months after the onset of AA (median, 2.5 mo; range, 1--9 mo). Six patients died of sepsis secondary to the following: gram-negative sepsis,[@R22],[@R73] *Zygomycetes* pneumonia,[@R89] unspecified pneumonia,[@R77] disseminated sepsis with cellulitis,[@R58] and *Escherichia coli* and *Streptococcus pneumoniae*.[@R58] One patient died of an unspecified infection and bleeding,[@R73] 1 died of an aortic aneurysm rupture,[@R58] and 1 died of an intracranial hemorrhage.[@R58] Five of these patients were treated with corticosteroids and various other drugs, including androgens but not ATG or CsA for AA.[@R58],[@R77] Additionally, 4 patients were treated with corticosteroids, ATG, and other drugs, excluding CsA.[@R22],[@R73],[@R89] Among these 4 patients, 1 underwent allogeneic HSCT from an unrelated donor[@R73] but eventually died 86 days after the transplantation.

###### 

Treatment Regimens and Outcome in 19 Patients With EF-Associated AA, Present and Previous Reports
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Long-term remission (\>2 yr) was reported in only 5 patients. One was treated with high-dose corticosteroids and plasma exchanges (3 yr of follow-up),[@R95] whereas corticosteroids alone or together with androgens failed to improve the aplasia in all other cases. Two patients were treated with HSCT from a sibling donor[@R24],[@R73] and had remission over 43 months of follow-up in the first case and 12 years in the second case. Patient 4 received a combination of CsA and ATG (17 yr of follow-up). The last patient with long-term remission was treated with CsA, corticosteroids and splenectomy (30 mo of follow-up after starting treatment).[@R117]

The combination of ATG and CsA is the current standard first-line therapy for patients with SAA and no available HLA-matched sibling donor.[@R130] It has proven effective in randomized controlled trials, and an overall response is achieved in two-thirds of the patients, with a cumulative incidence of relapse of 20%--30% among responders. Allogeneic HSCT is considered a first-line therapy in patients with available HLA-matched related donors.[@R130] Of the 6 patients with EF and AA who received ATG and CsA, 5 (83%) were partial (n = 3) or complete (n = 2) responders. Therefore, in this small number of patients with EF and SAA, the prognosis after standard immunosuppressive therapy seemed to be similar to that of isolated SAA in clinical trials.

Finally, Patient 2 underwent 2 courses of rituximab therapy (375 mg/m^2^ per infusion, 4 monthly infusions during each course) with remission of both the skin and hematologic disorders 15 months after treatment, whereas ATG and CsA alone did not show efficacy after 15 months. To our knowledge, rituximab has shown efficacy in EF treatment in only 1 other single reported case[@R102] and in AA in 3 cases with 5 months,[@R49] 4 years,[@R121] and 6 months[@R1] of follow-up. The last case had AA related to systemic lupus erythematosus.

The evolutions of EF and AA were not always correlated. Unlike systemic sclerosis, EF is usually corticosteroid-sensitive. Thus, prednisone monotherapy proved effective in 42 of 55 patients (76%) in 4 recent studies[@R2],[@R12],[@R76],[@R88] and in 25 of 34 patients (74%) in the Lakhanpal case series.[@R75] Among the 12 patients demonstrating AA associated with EF who were treated with corticosteroids as either monotherapy[@R73] or in addition to ATG,[@R117] CsA,[@R2] or colchicine,[@R22] and for whom skin outcome data were available, only 5 (42%) showed EF improvement[@R2],[@R22],[@R73] or remission.[@R117] In the 7 remaining cases (Patients 3 and 4 and patients from the literature[@R24],[@R30],[@R58],[@R77]), no skin improvement was observed after corticosteroid therapy. It could be assumed that patients with EF and associated AA had more corticosteroid-resistant EF than patients with isolated EF; however, the mean delay between treatment initiation and the assessment of efficacy was short (mean, 3.5 mo; range, 1--6 mo), and the small number of patients does not allow us to draw firm conclusions.

Among the 4 patients who died of AA and for whom skin outcomes were available, 3 achieved partial improvement of EF,[@R22],[@R73],[@R77] and 1 did not show improvement.[@R58] In the same way, 2 of our patients achieved complete (Patient 1) or almost complete (Patient 3) skin remission; however, they were still reliant on transfusions after ATG and CsA therapy. The 8 remaining patients for whom AA and EF outcomes were available (Patients 2 and 4 and patients reported previously[@R13],[@R24],[@R30],[@R73],[@R117]) achieved both hematologic and skin improvement or remission. In the patients who had relapses of AA, no concomitant relapse of EF was described.

A small-cell lymphoproliferative disorder was revealed after the autopsy of 1 patient,[@R57] but no other cases of evolving malignancy were described in the 18 remaining cases, nor were any found in our patients even after long-term follow-up.

Summary and Conclusions
-----------------------

We studied 4 patients with EF and associated SAA and reviewed 19 cases retrospectively. According to the data in the literature, AA seems to be the most frequently recorded hematologic disease associated with EF. It was the direct cause of death in at least 8 of 23 cases (35%). Compared to patients with isolated EF, patients with EF and associated AA were more likely to be men (70%) and older (mean age, 56 yr; range, 18--71 yr). It should be noted that unusual clinical features in the context of EF, such as systemic involvement (n = 7), Raynaud phenomenon (n = 1), calcinosis cutis (n = 1), and facial skin sclerosis (n = 2), were not rare in patients with EF and associated AA, even though they are usually considered to be the hallmark of systemic sclerosis. Four patients had other associated immune diseases: ulcerative colitis (n = 2), autoimmune thyroiditis (n = 2), and autoimmune cytopenias (n = 4). No clonal myeloid disorders were detected in these 23 patients.

The evolutions of EF and AA were not always correlated: remission of EF was not predictive of AA improvement, and no relapse of EF was observed in patients with AA relapses. Corticosteroid-containing regimens improved the skin condition in 5 of 12 cases (42%) but were ineffective in treating aplasia in 5 of 6 cases (83%). Among our 3 patients who were refractory to ATG and CsA, 1 had 2 courses of rituximab therapy with both skin and hematologic improvement. Finally, long-term remission (\>2 yr) was reported in 5 cases with the following treatments: corticosteroid-containing regimen (n = 1), allogeneic HSCT from sibling donor (n = 2), and CsA-containing regimen (n = 2). In conclusion, patients with EF should be carefully monitored for associated AA, which occurs mostly in the first year after EF diagnosis. AA in this setting is usually severe and rapidly life-threatening in the absence of early immunosuppressive therapy. The response of AA to immunosuppressive therapy can be slow, even after EF remission, and AA relapse does occur. Therefore, long-term suppressive treatment with CsA is recommended. Allogeneic HSCT should be considered in patients with an available HLA-matched related donor.
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AA

:   aplastic anemia

ATG

:   antithymocyte globulin

CsA

:   cyclosporine A

EF

:   eosinophilic fasciitis

HSCT

:   hematopoietic stem cell transplantation

PNH

:   paroxysmal nocturnal hemoglobinuria

SAA

:   severe aplastic anemia

Tregs

:   regulatory T cells
